Kingsley L. Taft

Kingsley L. Taft

he/him/his
Partner Co-Chair, Life Sciences Practice
Kingsley L. Taft

Kingsley Taft is a senior partner and co-chair of Goodwin's Life Sciences group and member of the Allocations Committee. He represents emerging to mature life sciences companies in all aspects of their business and legal affairs, including company formation, venture financings, strategic alliances, M&A, IPOs and other capital market transactions, and other financing and commercial transactions. Mr. Taft has extensive experience in assisting clients with JVs, strategic alliances, licenses, and collaborations.

Mr. Taft has been recognized as a leading life sciences attorney by numerous legal guides. He has been annually ranked for more than 15 years in Chambers USA: America’s Leading Lawyers for Business (Nationwide, Life Sciences: Corporate/Commercial — Band 1). Mr. Taft was inducted into the LMG Life Sciences Hall of Fame, and named a Life Sciences Thought Leader by Who’s Who Legal - Global Elite.

Before attending Harvard Law School, Mr. Taft earned a B.S in Chemistry from Yale University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Representative Matters

REFERENZMANDATE

代表事项

Strategic Alliances and M&A
  • insitro on its collaboration with Bristol Myers Squibb for novel therapies to treat amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), with an upfront payment of $50 million, a near-term milestone of $20 million, royalties and up to an aggregate $2 billion in milestones
  • Vedere Bio on its acquisition by Novartis for $150 million upfront and up to $130 million in milestone payments, for an overall deal value of up to $280 million, for its novel optogenetics AAV gene therapy
  • SpringWorks Therapeutics on its exclusive arrangement with Jazz Pharmaceuticals for SpringWorks’ fatty acid amide hydrolase inhibitor program, for an upfront payment of $35 million, up to $375 million in milestones and royalties in the mid- to high-single digit percentages
  • Thrive Earlier Detection Corp. on its acquisition by Exact Sciences Corp. for cash and stock of $1.7 billion at closing and up to $450 million in milestones, for an overall deal value of up to $2.15 billion
  • HiFiBiO on its collaboration with Kite, a Gilead company, in acute myeloid leukemia
  • Teva Pharmaceuticals on its collaboration with Alvotech for the commercialization in the U.S. of five biosimilar product candidates, for an upfront payment, milestones and profit share
  • Blueprint Medicines on its global collaboration with F. Hoffmann-La Roche and Genentech for pralsetinib to treat cancer driven by oncogenic RET alterations, for an upfront of $675 million, equity investment of $100 million, up to $927 million in milestones, and a 50/50 US profit share and ex-US royalties
  • RTW Investments and Ji Xing Pharmaceuticals on a strategic licensing and financing collaboration with Cytokinetics, for committed capital, funding and sale proceeds of up to $250 million from and up to $200 million in milestone payments plus royalties on future sales in certain Asian countries
  • Corvidia Therapeutics in its acquisition by Novo Nordisk for $725 million up-front and up to $2.1 billion in total for transformative cardio-renal therapies
  • Alnylam Pharmaceuticals in its four strategic financing transactions with Blackstone for the advancement of innovative RNA interference (RNAi) medicines that have the potential to transform the lives of patients suffering from a range of debilitating diseases, valued at $2 billion
  • Arrakis Therapeutics in its strategic collaboration with Roche for the discovery of RNA-targeted small molecule (rSM) drugs against a broad set of targets across all of Roche’s research and development areas, for $190 million up-front and up to more than several billion dollars
  • Flexion Therapeutics in its exclusive license agreement with HK Tainuo and Jiangsu Tainuo (a subsidiary of China Shijiazhuang Pharmaceutical) for the development and commercialization of ZILRETTA in Greater China for an upfront payment of $10 million and up to more than $30 million in milestone payments
  • Promedior Inc. in its acquisition by Roche for $390 million up-front and up to $1.4 billion in total value, for its lead asset PRM-151 for treatment of idiopathic pulmonary fibrosis (IPF)
  • Semma Therapeutics in its acquisition by Vertex Pharmaceuticals for $950 million up-front, for its stem cell-derived human islets technology as a potentially curative treatment for type 1 diabetes
  • Ultragenyx in its partnership with GeneTx to advance treatment for Angelman Syndrome for $20 million up-front in return for an option to acquire the company
  • insitro in its strategic collaboration with Gilead Sciences to develop therapies for patients with nonalcoholic steatohepatitis (NASH), with up to $50 million in near-term payments and $1 billion in deal value
  • Alnylam Pharmaceuticals in its collaboration with Regeneron for new RNA interference (RNAi) therapeutics focused on ocular and central nervous system (CNS) diseases with announced deal value up to $1 billion, in $800 million through upfront cash and equity investment and $200 million in near-term milestones
  • Ipsen in its acquisition of Clementia Pharmaceuticals with a transaction value of $1.31 billion, including a CVR based on the multiple osteochondromas indication for palovarotene
  • Verseau Therapeutics on its partnership agreement with 3SBio Inc. focused on novel monoclonal antibodies in the field of immuno-oncology for a broad range of cancers, along with a $10 million Series B investment
  • Esperion Therapeutics in its agreement with Daiichi Sankyo Europe regarding bempedoic acid and combinations in Europe, for $300 million upfront, up to $900 million in total milestones, and royalties
  • Scholar Rock in its collaboration with Gilead Sciences for inhibitors of transforming growth factor beta (TGFβ) activation to treat fibrotic diseases, for $80 million up front and up to $1.4 billion in milestones
  • MacroGenics in its arrangement with Zai Lab for Margetuximab, MGD013 and a TRIDENT™ molecule in greater China, for $25 million upfront, up to $140 million in milestone payments, and double-digit royalties
  • SpringWorks Therapeutics in its global clinical collaboration with BeiGene to evaluate combining BeiGene’s investigational RAF dimer inhibitor and SpringWorks Therapeutics’ investigational MEK inhibitor
  • Ambys Medicines in forming a strategic partnership with Takeda and concurrent $140 million funding
  • Wave Life Sciences in its strategic collaboration with Takeda to develop nucleic acid therapies for disorders of the central nervous system for $110 million upfront and up to $2 billion in milestone payments
  • Aerpio Therapeutics in its global license agreement with Gossamer Bio, with $20 million up-front, potential milestones of up to $400 million, and royalties ranging from a high single digit to mid-teen percentage
  • Foundation Medicine in its collaboration agreement and equity transaction with Roche, with total deal value in excess of $1 billion and subsequent merger with Roche valued at $2.4 billion
  • Moderna Therapeutics in numerous strategic transactions with AstraZeneca, Merck and others with upfront deal value in excess of $1 billion in cash and equity, plus downstream payments
  • Fresenius Medical Care in global partnership with Humacyte to commercialize the investigational human acellular vessel HUMACYL; Fresenius made a $150 million equity investment in Humacyte
  • Warp Drive Bio in its collaboration with Roche on novel classes of antibiotics, valued up to $387 million
  • Dimension Therapeutics in its $151 tender offer and contested sale to Ultragenyx
  • Teva Pharmaceuticals in three related sales of its specialty global women’s health business for a combined deal value of $2.5 billion, CooperSurgical, CVC Capital Partners and Foundation Consumer Healthcare
  • Delinia Therapeutics in its sale to Celgene, valued up to $775 million with up-front payment of $300 million
  • Pieris Pharmaceuticals in its strategic collaboration with AstraZeneca to develop novel inhaled drugs that leverage Pieris’ Anticalin platform, for deal value of up to $2.1 billion
  • Medicxi Ventures as an investor in Impact Biomedicines in its sale to Celgene for up to $7 billion
  • Royalty Pharma in its acquisition from Perrigo Company of royalty rights to Tysabri for up to $2.8 billion
  • Teva Pharmaceuticals in its global agreement with Regeneron for the phase 3 novel nerve growth factor antibody fasinumab, for $250 million upfront and a share in its global commercial value
  • Pieris Pharmaceuticals in its collaboration with Servier for a dual-checkpoint inhibitor and up to seven other immuno-oncology bispecific drug candidates, for a deal value of up to €1.7 billion
  • Morgan Stanley as financial advisor to Stemcentrx in its sale to AbbVie for $5.8 billion in cash and stock, and up to an additional $4 billion in cash in success-based milestone payments
  • Intellia Therapeutics in its multi-year collaboration with Regeneron on CRISPR/Cas gene-editing technology for in vivo therapeutic development, with $75 million upfront and potential milestone and royalty payments
  • Padlock Therapeutics in its sale to Bristol-Myers Squibb, valued up to $600 million with up-front and near-term payments of $225 million
  • Blueprint Medicines in its collaboration with Roche, up to $1 billion in value with $45 million upfront
  • Surface Oncology in its collaboration with Novartis to develop next generation immunotherapeutics, with Surface to receive up to $170 million in near term cash, plus milestones and royalties
  • Promedior in its option agreement with Bristol-Myers Squibb with potential deal value of up to $1.25 billion
  • Unum Therapeutics in its strategic collaboration with Seattle Genetics to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer, with potential deal value of $615 million
  • Teva Pharmaceuticals in its acquisition of Labrys Biologics, for $200 million cash and up to $825 million 
  • Nogra Pharma in its $710 million global license agreement with Celgene for therapies to treat Crohn’s disease with a total potential deal value up to $2.6 billion in milestones, plus royalties
  • bluebird bio in its global collaboration with Celgene and subsequent update for gene therapies to treat cancer with deal value up to $300 million
Public Offerings
  • SpringWorks Therapeutics in its $186.3 million initial public offering and $287.5 million follow-on offering 
  • Kaleido Biosciences in its $75 million initial public offering and its $35.6 million follow-on offering
  • Scholar Rock in its $86 million initial public offering, and subsequent $51 million and $230 million follow-on offerings
  • Axcella Health in its $71 million initial public offering
  • HOOKIPA Pharma in its $84 million initial public offering
  • Moderna Therapeutics in its $604 million initial public offering and follow-on offerings
  • Blueprint Medicines in its $147 million initial public offering and subsequent $143 million, $230 million, $350 million, and $327 million follow-on offerings
  • Aerpio Therapeutics in its $40 million reverse merger and private placement and subsequent $45 million follow-on offering and up-listing to NASDAQ
  • Surface Oncology in its $108 million initial public offering and concurrent $11.5 million private placement
  • Unum Therapeutics in its $69 million initial public offering and concurrent $5 million private placement
  • aTyr Pharma in its $75 million initial public offering and $45 million subsequent equity financing
  • Fate Therapeutics in its $40 million IPO, $30 million follow-on offering, and $57 million structured PIPE
  • Ra Pharmaceuticals in its $105 million initial public offering
  • Dimension Therapeutics in its $72 million initial public offering
  • Foundation Medicine in its $106 million initial public offering
Venture/Mezzanine Financings
  • AbSci on its $65 million Series E equity financing to increase production capacity, accelerate facility expansion and support research and development activities
  • Palleon Pharmaceuticals in its $100 million Series B to develop drugs targeting glycan-mediated immune regulation to treat cancer and inflammatory diseases 
  • InterVenn Biosciences on its $34 million Series B fundraising to commercialize the company’s High-Throughput-Glycoproteomic powered diagnostic for ovarian cancer and to accelerate development efforts for the immuno-oncology treatment response and colorectal cancer indications
  • Q32 Bio on its $60 million Series B financing to propel the company’s groundbreaking tissue-targeted complement regulation platform
  • Hillhouse Capital on its investment in Everest Medicines as a co-lead investor in Everest Medicine’s Series C financing of $310 million
  • Cerevance on its $45 million Series B financing to identify novel therapeutic targets for central nervous system diseases
  • Moma Therapeutics on its launch and $86 million Series A financing to establish a platform focused on the drug discovery of molecular machines
  • Xilio Therapeutics on its $100.5 million Series B financing to progress Xilio’s first two therapeutic candidates, XTX201 (tumor-selective IL-2) and XTX101 (tumor-selective aCTLA4 mAb)
  • EQRx in its $200 million Series A financing to create novel, patent-protected medicines at prices that are more affordable for people and sustainable for healthcare systems
  • Triplet Therapeutics, Inc. in its $49 million Series A financing to further its development of transformative treatments for Triplet repeat disorders
  • Verseau Therapeutics in its launch and $50 million financing to create a new class of therapeutics, macrophage checkpoint modulators to benefit patients with cancer, immune and inflammatory diseases
  • Arrakis Therapeutics in its $75 million Series B financing to advance a new class of small-molecule medicines targeting RNA
  • SpringWorks Therapeutics in its $125 million Series B financing to advance two late-stage rare disease oncology programs toward potential regulatory approval
  • Medicxi Ventures in its $40 million Series D financing of Aura Biosciences for ocular melanoma treatments
  • HOOKIPA Pharma in its $37.4 Series D financing to advance its clinical programs
  • Cadent Therapeutics in its $40 million financing round to advance its pipeline of novel therapies for movement and cognitive disorders
  • Akrevia in its $30 million financing to develop highly-potent, targeted immuno-oncology therapeutics
  • Rheostat Therapeutics in its $23 million financing to develop treatments for neurodegenerative disease
  • Alector Corporation in its most recent $133 million financing and prior $29.5 million financing to advance a broad portfolio of IO programs
  • Kaleido Biosciences in its most recent $101 million financing and prior $85 million financing to develop novel chemistries for the human microbiome
  • Corvidia Therapeutics in its most recent $60 million financing and prior $26 million financing and in-license of a clinical stage asset from AstraZeneca to advance its lead clinical programs in chronic kidney disease 
  • Quentis Therapeutics in its $48 million financing for cancer immunotherapies 
  • Moderna Therapeutics in its most recent $500 million and prior $474 million and $450 equity financings to pioneer mRNA therapeutics
  • Semma Therapeutics in its most recent $114 million financing and prior $44 million financing for stem cell therapies for Type 1 diabetes
  • Arrakis Therapeutics in its $38 million financing to discover a new class of medicines directly targeting RNA
  • Cerevance in its $40 million plus funding and spin-out from Takeda Pharmaceutical for neuroscience
  • Axcella Health in its approximately $80 million financing for amino acid-based products
  • Medicxi Ventures in its approximately $22 million financing of Impact Biomedicines to develop treatments for myeloproliferative neoplasms and other cancers
  • SetPoint Medical in its $100 plus million in financings for its implantable neuromodulation devices
  • Scholar Rock in its $47 million financing and earlier preferred stock financings for therapeutics that target specific growth factors
  • Unum Therapeutics in its $65 million financing for its anti-body directed cellular immunotherapies
  • Surface Oncology in its $35 million financing for cancer immunotherapies
  • Aerpio Therapeutics in its $60 million financings for vascular disease therapies

Recognition

Mr. Taft has been recognized by numerous legal guides for legal and life sciences industry expertise. In addition to the two listings noted above, Mr. Taft has also been named as a leading business lawyer by Chambers GlobalU.S. News-Best Lawyers (Biotechnology Law), Chambers Global (Life Sciences: Corporate/Commercial), IFLR1000 (Pharmaceutical sector), LMG Life Sciences (Life Sciences Star), The Legal 500 United States (Healthcare: Life Sciences and Venture Capital and Emerging Companies), PLC Cross-border Life Sciences Handbook (Commercial and Partnering), named to the IAM Global Leaders Guide (2020), IAM Patent 1000 (Licensing), and The International Who’s Who of Life Sciences Lawyers (Transactional).

Under his leadership, Goodwin’s Life Sciences Practice has received numerous awards and honors, including U.S. News’ Biotechnology Law Firm of the Year for four out of five years running (2013 through 2015, and 2017), Law360 Life Sciences Group of the Year (2016), LMG Life Sciences’ Corporate Law Firm of the Year (2019) and Venture Capital Law Firm of the Year (2016), and perennial nationwide recognition by Chambers USA.

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 1997
Harvard Law School

(magna cum laude)

Ph.D., Chemistry, 1993
Massachusetts Institute of Technology
B.S., Chemistry, 1989
Yale University

(magna cum laude)

Clerkships

1997 to 1998 U.S. Court of Appeals for the Federal Circuit, Honorable Raymond C. Clevenger

Admissions

Bar

Massachusetts
Profile Image
Get In Touch
Kontakt
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师